iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)											1 Months Ended						3 Months Ended			6 Months Ended	8 Months Ended	12 Months Ended
Basis of Presentation (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2020	Jun. 17, 2020	Mar. 19, 2020	Mar. 13, 2020	Oct. 29, 2019	Mar. 19, 2019	Jul. 12, 2018	Jul. 12, 2018	Jun. 26, 2018	Jul. 31, 2020	Jul. 27, 2020	Jun. 30, 2020	Nov. 30, 2018	Jun. 26, 2018	Jun. 26, 2018	Oct. 13, 2020	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Oct. 08, 2020	Jun. 30, 2018	Jun. 30, 2016
Basis of Presentation [Line Items]
Accumulated deficit	$ (150,420,000)	$ (150,420,000)											$ (150,420,000)								$ (150,420,000)	$ (150,420,000)	$ (105,821,000)
Net Cash Used in Operating Activities																						(13,345,000)	(13,975,000)
Cash	55,112,000	55,112,000											55,112,000								55,112,000	55,112,000	4,421,000		$ 4,421,000	$ 15,934,000
Cash and marketable securities																								$ 83,000,000
Proceeds from the exercise of warrants																					6,400,000	6,330,000	0
Net proceeds from underwritten public offering										$ 16,000,000
Stock Issued During Period, Value, New Issues						$ 4,500,000										$ 16,000,000							0
Shares of the common stock issued										4,350,000						4,350,000
Shares Issued, Price Per Share										$ 0.90					$ 0.90	$ 0.90
Gross proceeds from issuance						$ 4,520,000
Advance received																						6,300,000
Purchase of capital expenditure																						31,400,000
Sale of Stock, Consideration Received on Transaction										$ 16,000,000
Contract liabilities	$ 1,810,000	$ 1,810,000											$ 1,810,000								$ 1,810,000	1,810,000	1,279,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized										2,666,666
Contract with Customer, Liability																							1,800,000
Contract with Customer, Liability, Revenue Recognized																			$ 3,100,000			1,279,000	1,279,000
Proceeds from capital contribution																						$ 0	2,459,000
Stock Issued During Period, Shares, Warrants Exercised																					29,100,000
Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues					$ 1,100,000
Shares of the common stock issued		16,800,000		815,827	1,000,000																	16,800,000
Shares Issued, Price Per Share					$ 1.09
Number of shares offered				1,000,000
Gross proceeds from issuance		$ 18,400,000					$ 50,000,000															$ 18,400,000
Net Proceeds From Issuance Of Common Stock Shares																						19,800,000
Net Proceeds From Issuance Of Common Stock																						$ 42,200,000
Authorized value of shares				$ 50,000,000
Term of agreement				36 months			36 months
Lung Bio
Basis of Presentation [Line Items]
Advance received																		$ 1,600,000
Contract with Customer, Liability, Revenue Recognized																						46,000
CC-Pharming Ltd
Basis of Presentation [Line Items]
Contract with Customer, Liability, Revenue Recognized																						$ 1,300,000
Master Manufacturing Services and Supply Agreement ("MSA")
Basis of Presentation [Line Items]
Purchase of capital expenditure																		1,000,000
Related contracted services																		620,000
Contract liabilities																		$ 1,600,000
Eastern Affiliate [Member]
Basis of Presentation [Line Items]
Proceeds from capital contribution														$ 2,500,000
Over-Allotment Option [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues									$ 1,350,000
Shares of the common stock issued									1,500,000
Shares Issued, Price Per Share								$ 0.90	$ 0.90
Number of shares offered																2,666,666
Gross proceeds from issuance								$ 1,350,000
Common Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues																							$ 1,000
Shares of the common stock issued						2,450,000																	142,000
Shares Issued, Price Per Share										$ 0.90					$ 0.90	$ 0.90
Stock Issued During Period, Shares, Warrants Exercised																						35,000,000
Series A Warrants [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued						25,000,000														3,300,000
Series A Preferred Stock [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued										6,300					6,300
Series B Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues										$ 5,785
Shares of the common stock issued										5,785
Shares Issued, Price Per Share						$ 0.20
Subsequent event \| Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Shares of the common stock issued											2,700,000	2,670,000
Gross proceeds from issuance											$ 6,800,000	$ 6,790,000
Net Proceeds From Issuance Of Common Stock Shares											8,600,000
Net Proceeds From Issuance Of Common Stock											$ 24,600,000
UBS Securities, LLC ("UBS")
Basis of Presentation [Line Items]
Net proceeds from underwritten public offering			$ 72,000,000
Shares of the common stock issued	17,400,000
Gross proceeds from issuance	$ 37,800,000
Sale of Stock, Consideration Received on Transaction			$ 72,000,000
UBS Securities, LLC ("UBS") \| Common Stock [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued													2,400,000				8,600,000
Net Proceeds From Issuance Of Common Stock													$ 5,550,000				$ 24,600,000